Search alternatives:
per decrease » _ decrease (Expand Search)
11 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
9 11 » _ 11 (Expand Search)
per decrease » _ decrease (Expand Search)
11 decrease » _ decrease (Expand Search)
nn decrease » _ decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
9 11 » _ 11 (Expand Search)
-
861
Salvia fruticosa Induces Vasorelaxation in Rat Isolated Thoracic Aorta: Role of the PI3K/Akt/eNOS/NO/cGMP Signaling Pathway
Published 2017“…Pretreatment of endothelium-intact rings with L-NAME (a non-selective inhibitor of nitric oxide synthase, 100 µM), or ODQ (an inhibitor of soluble guanylyl cyclase, 10 µM) significantly diminished SF-mediated vasorelaxation. …”
Get full text
Get full text
-
862
-
863
-
864
-
865
-
866
-
867
-
868
Repositioning for pressure injury prevention in adults.
Published 2020“…The intervention was reported to be cost-saving compared with standard care (nursing time cost per patient EUR 206.60 versus EUR 253.10, incremental difference EUR -46.50, 95% CI EUR -1.25 to EUR -74.60). …”
Get full text
Get full text
-
869
-
870
-
871
Evaluation of different personalized ventilation air terminal devices: Inhalation vs. clothing-mediated exposures
Published 2021“…The model was validated experimentally in a climatic chamber by comparing real-time particle mass concentration near a thermal manikin. …”
Get full text
Get full text
-
872
-
873
-
874
-
875
-
876
Electrically conductive hybrid organic crystals as flexible optical waveguides
Published 2022“…In cyclic operation mode, their conductivity decreases less than 1% after 10,000 thermal cycles. …”
Get full text
-
877
-
878
-
879
Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
Published 2023“…Results The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3%) in 2015 to 1342 (28.9%) in 2020 (p <0.001). Within BMI categories, a similar increasing trend was observed in underweight, normal, and overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban prescribing in all obese classes. …”
Get full text
Get full text
-
880